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Retinoic acid (RA) plays an important role in the commitment, maturation and
survival of neural cells. Recently, RA was pointed as a therapeutic option for some
neurodegenerative diseases, including Parkinson’s disease (PD). The administration
of RA has been defying, and in this sense we have previously developed novel
RA-loaded polymeric nanoparticles (RA-NPs) that ensure the efficient intracellular
transport and controlled release of RA. Herein, we show that nanoformulation as an
efficient neuroprotective effect on dopaminergic (DA) neurons in the 1-methyl-4-phenyl-1,
2, 3, 6-tetrahydropyridine (MPTP) induced mouse model for PD. The results showed
that the RA-NPs administration induced a significant reduction of DA neuron loss in the
substantia nigra (SN) as well as their neuronal fiber/axonal innervations in the striatum.
Furthermore, we observed an increase in the expression levels of the transcription factors
Pitx3 and Nurr1 induced by RA-NPs, showing its supportive effect on the development
and functional maintenance of DA neurons in PD. This is the first study showing that
RA-NPs can be an innovative strategy to halt the progression of PD pathogenesis,
suggesting that this nanoformulation could be of particular interest for the development
of new approaches for PD therapeutics.
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Introduction
Retinoic acid (RA) is a metabolic product of vitamin A (retinol) which plays important roles in
the development of mammalian nervous system (Maden, 2007). RA has been also highlighted
as a therapeutic option for some neurodegenerative disorders, including in Parkinson’s disease
(PD). RA is likely to be important for midbrain dopaminergic (mDA) neurons since its recep-
tors and RA-synthesizing enzymes are highly expressed both in these neurons and their target
regions (McCaffery and Drager, 1994). The RA signal is transduced by specific nuclear recep-
tors: retinoic acid receptors (RAR) and retinoid X receptors (RXR), which are members of the
nuclear receptor superfamily (Kastner et al., 1997). These receptors heterodimerize and bind to
a DNA sequence called retinoic acid-response element (RARE) and induce gene transcription
(Bastien and Rochette-Egly, 2004). Several evidences suggest an involvement of RA signaling in
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the development, maintenance and protection of the nigrostri-
atal pathway; however the cellular and molecular mechanisms
underlying these effects are not yet known. Most importantly,
it was shown that stimulation of RAR with RAR agonist AM80,
prevented DA cell loss induced by lipopolysaccharide (LPS) in
the substantia nigra (SN) (Katsuki et al., 2009). In accordance,
it was shown by Yin and collaborators that the intranasal deliv-
ery of RA reduces neurodegeneration of DA neurons induced
by 6-hydroxidopamine (6-OHDA) (Yin et al., 2012). Clinically,
there is a marked reduction in the expression levels of the enzyme
retinaldehyde dehydrogenase 1 (RALDH1), which is necessary
for the conversion of retinaldehyde to RA, in the mDA neu-
rons of post-mortem brain PD patients (Galter et al., 2003). The
RALDH1 expression levels found in peripheral blood have been
recently reported as a candidate biomarker for PD diagnosis
(Grunblatt et al., 2010). However, it is not possible to know if this
decrease in RALDH1 gene expression precedes the onset of PD or
is a consequence of the degenerative process. It may be possible
that the reduced availability of RA in the midbrain might be due
to the reduced RALDH1 expression, which in turn increases the
susceptibility of the mDA neurons to the degenerative processes,
pushing the balance toward neuronal death instead of neuropro-
tection. Mutations in the gene coding for this enzyme was also
shown to represent a genetic risk factor for human PD either
alone or in conjunction with other environmental risk factors
(Buervenich et al., 2005).
The administration of RA is challenging due to its undesir-
able properties, like poor water solubility, short half-life, requires
a fine-tuning of the concentration window to achieve its effects,
posing difficulties in the delivery of therapeutic doses (Szuts and
Harosi, 1991). Therefore, we recently developed nanoparticles
(NPs) loaded with all-trans retinoic acid (atRA) as an alternative
to control the undesired side effects and to ensure intracellular
transport and controlled release of RA. A successful approachwas
achieved by approximately 200 nm-sized NPs which were rapidly
taken up by cells, delivering RA intracellularly (Maia et al., 2011).
Several NPs formulations have been reported for the controlled
release of this molecule (Castro et al., 2007; Narvekar et al., 2012);
however, none of these formulations were designed to deliver
RA for DA neuroprotection. It was shown previously by our
group that the internalization of the atRA-loaded polymeric NPs
(RA-NPs) has a minimal effect on cell viability and proliferation
but enhanced neurogenesis at the subventricular zone stem cell
niche, both in vitro and in vivo (Maia et al., 2011; Santos et al.,
2012).
In the present study, we examined the putative neuropro-
tective effect of NPs-encapsulated RA in a PD mouse model.
In addition to that, the expression of Nurr1 and Pitx3 both at
mRNA and protein levels were examined in SN and striatum
as these two transcription factors are involved in the develop-
ment, survival and specification of DA neurons.With the present
results we have proved that this RA-NPs formulation may create
a favorable environment to protect DA neurons in the nigros-
triatal pathway, as well as by preventing the decrease of mRNA
and protein expression of transcription factors involved in DA
neurons maintenance. This work reports for the first time a RA-
releasing nanoformulation as an efficient strategy to prevent the
onset of PD, and possibly to open new therapeutic perspectives
for the treatment of other neurodegenerative diseases.
Materials and Methods
Animals
Young adult (2–3 months old) and old (25–26 months old) male
C57BL6 mice were used for this study. All animals were handled
in accordance with protocols approved by the national ethical
requirements for animal research, and in accordance with the
Directive 2010/63/EU of the European Parliament and the Coun-
cil on the protection of animals used for scientific purposes. Mice
were kept in appropriate cages, under temperature-controlled
conditions with a fixed 12 h light/dark cycle, food andwater freely
available. All efforts were made to reduce the number of animals
to be used for the study and to minimize their suffering.
Stereotaxic Injection
Both young adult and old mice were anesthetized with intraperi-
toneal (i.p.) injection of ketamine (90mg/kg of mouse weight)
and xylazine (10mg/kg of mouse weight) and placed in a stereo-
taxic frame. The skull was exposed and the scales were defined
after setting the zero at the bregma point. Mice were then
unilaterally injected in the right lateral striatum (X,AP: +0.6;
Y,ML:−1.8; Z,DV:−2.8mm, Paxinos and Franklin, 2001), which
was considered the ipsilateral side, with 100 ng/ml RA-NPs (dis-
solved in sterile phosphate buffer saline, PBS: NaCl 140mM,
KCl 2.7mM, KH2PO4 1.5mM and Na2HPO4 8.1mM, pH 7.4),
100 ng/ml blank NPs (void formulation; dissolved in PBS), 4 nM
or 10µM solubilized atRA (dissolved in dimethyl sulfoxide
(DMSO); final dilution of 1:250,00000 and 1:10,000, respectively),
or sterile 0.1M PBS (vehicle) through a 10µl Hamilton syringe at
a speed of 0.2µl/min over 5min. The contralateral side was the
left lateral striatum and remains uninjected. The atRA was used
as this is the prevalent functionally active isoform of RA. RA-NPs,
blank NPs and solubilized atRA were prepared freshly just before
the injections and the solubilized atRA solution was protected
from light and kept on ice until injection. The concentrations
of RA-NPs, blank NPs and solubilized atRA were chosen based
in previous studies developed by us (Maia et al., 2011; Santos
et al., 2012). The vehicle used for the NPs formulations was 0.1M
sterile PBS.
MPTP-Induced Lesion and Tissue Processing
MPTP administration was given 3 days after intrastriatal injec-
tions of nanoparticles formulations. MPTP (Sigma-Aldrich, St.
Louis, MO, USA) was dissolved in sterile 0.9% NaCl and injected
via i.p. in four sessions separated by 2 h intervals. The dose used
was 15mg/kg body weigh in adult mice (Kong et al., 2008) and
7mg/kg body weight in old mice (Peng and Andersen, 2011),
been the total dose after the 4 injections of 60 and 28mg/kg,
respectively. The saline group animals, subjected to the same
stereotaxic procedure, received an equivalent volume of sterile
0.9% NaCl. Seven days after the MPTP exposure (Figure 1), one
group of animals was anesthetized with ketamine and euthanized
by transcardial perfusion with 0.9% NaCl followed by perfu-
sion with 4% paraformaldehyde (PFA) and the brains were then
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FIGURE 1 | Timeline for experimental treatments and assays performed in vivo.
recovered. Brains were post-fixed by immersion in 4% PFA solu-
tion, transferred to 30% sucrose (in PBS) and then frozen. After-
ward, brains were coronally sectioned at a thickness of 35µm
from the frontal pole to the midbrain on a freezing cryostat-
microtome (Leica CM 3050S, Leica Microsystems, Nussloch,
Germany) at −20◦C. The sections encompassing the SN and the
striatum of each animal were collected sequentially to six well
of 24-well plate, and stored in PBS supplemented with 0.02%
sodium azide at 4◦C, until processed for immunohistostainings.
Another group of animals was euthanized by spinal cord dis-
location, the brains were removed and the regions of interest,
SN and striatum, were quickly dissected from both hemispheres
and stored at −80◦C for RNA and protein expression analysis
by quantitative real-time polymerase chain reaction (qPCR) and
western-blot, respectively.
Tyrosine Hydroxylase (TH) Immunohistostaining
The TH immunohistostaining was carried out to detect DA neu-
rons in the SN and striatal TH fibers in the striatum. Coronal
sections were incubated on a 10mM citrate solution (pH 6.0)
at 80◦C for 30min for antigen retrieval. After cooled to room
temperature (RT), sections were placed in water for 5min and
then washed with PBS-Tween 20 (PBS-T). Sections were then
incubated with PBS containing 10% fetal bovine serum (FBS)
and 0.1% Triton X-100 for at least 1 h at RT. Endogenous per-
oxidase activity was inhibited by incubation with 3% hydrogen
peroxide (H2O2) in water for 10min at RT and the sections
were then washed with PBS-T. Sections were incubated with pri-
mary antibody mouse anti-TH (dilution 1:1000; Transduction
Laboratories, Lexington, NY, USA) diluted in PBS containing 5%
FBS, overnight at 4◦C. After several rinses with PBS-T, sections
were incubated with a biotinylated goat anti-mouse secondary
antibody (dilution 1:200; Vector Laboratories, Burlingame, CA,
USA) diluted in PBS containing 1% FBS for 1 h at RT. The avidin-
biotin peroxidase complex reagent (Vectastain ABC KIT, Vec-
tor Laboratories Inc., Burlingame, CA, USA) was then added
for at least 30min at RT. The reaction product was visualized
using 3, 3′-diaminobenzidine (DAB) (Sigma) in Tris buffer saline
(TBS: 20mMTris and 137mMNaCl solution, pH 7.6) containing
0.08% H2O2 until color develops (5–10min). The reaction was
stopped by adding TBS. Sections were mounted on slides, dried
and dehydrated in graded ethanol dilutions, cleared in xylene
and cover slipped using a permanent mounting medium (Entel-
lan, Merck, NJ, USA). Quantitative analysis of DA neurons in
SN was carried out by serial section analysis of the total num-
ber of TH positive (TH+) neurons throughout the rostro-caudal
axis. Only the region corresponding to the SNwas carefully delin-
eated, according to the mouse brain atlas of Paxinos and Franklin
(Paxinos and Franklin, 2001), and the total number of TH+ neu-
rons in the full extent of this structure was counted blind to
control, per section in each hemisphere. The total number of
TH+ neurons for each representative mesencephalic section was
quantified in four coronal sections per mouse serially selected
from −2.80 to −3.80mm relative to bregma, under the mag-
nification of 10x at the Zeiss Axiovert 200 imaging microscope
(Axiobserver Z1, Carl Zeiss, Oberkochen, Germany). Quantita-
tive analysis of the intensity and area occupied by TH+ fibers
staining in striatum was carried out in four serially selected
coronal sections of striatum, from 1.10 to 0.38mm relative to
bregma of each mouse, selected throughout the rostro-caudal
axis, under the magnification of 5x at the Zeiss Axiovert 200
imaging microscope.
Total RNA Extraction and cDNA Synthesis
Total RNA was extracted from the striatum and SN using illus-
tra RNAspin Mini RNA isolation Kit (GE Healthcare UK Lim-
ited, Buckinghamshire, UK, Cat no. 25-0500-71) according to
manufacturer’s protocol (Santos et al., 2012). Briefly, the samples
were first lysed in lysis solution containing guanidine thiocyanate
which ensured the inactivation of RNases. Samples were applied
to spin mini filters to filtrate the lysate and the remaining filter
was discarded. Afterwards, 70% ethanol was added to the fil-
trate to complex and precipitate nucleic acids. Samples were then
transferred to spin mini columns where total RNA bound to the
membrane. Then, salts were removed from silica membrane by
the addition of desalting buffer therefore allowing a more effi-
cient DNA digestion with DNase I. After incubation with DNase
I, the column was washed and dried by the addition of a series
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of wash buffers promoting inactivation of DNase I and remov-
ing contaminants from the membrane-bound RNA, allowing the
purification of high-quality mRNA enriched solution. At the end,
mRNA samples were dissolved in 25µl of RNase-free water and
the total amount of mRNA was quantified by the nanopho-
tometer (Implen) at 260 nm, and the purity was determined by
measuring the 260/280 nm ratio. cDNA synthesis was performed
using transcriptor first strand cDNA synthesis Kit (Roche, Basel,
Switzerland, Cat no. 4379012001) according to the manufac-
turer’s instructions. Briefly, total mRNA extracted from adult
(0.2µg) and old mice (0.4µg) tissue samples was mixed with 1µl
anchored-oligo (dT) 18 primers, 4µl reverse transcriptase reac-
tion buffer 5x, 0.5µl RNase inhibitor, 2µl deoxynucleotide mix
(dNTPs), 0.5µl reverse transcriptase and sterile water in a 20µl
final volume. The reaction was performed at 55◦C for 30min
and stopped at 85◦C for 5min step by a thermocycler (Biome-
tra, Goetting, Germany). The samples were then stored at−80◦C
until further use.
Quantitative Real-Time PCR (qPCR)
The qPCR assays for gene expression analysis of Nurr1 in the
striatum and SN and Pitx3 in the SN were performed by adding
2µl of cDNA sample, 10µl SYBR Green Supermix (BioRad Lab-
oratories, CA, USA), 1/10 dilution of each primer (according to
primers datasheet) and RNase free water to a 20µl total volume.
The reaction was initiated with activation of Taq polymerase by
heating at 94◦C during 3min followed by 40 cycles of a 15 s
denaturation step at 94◦C and a 30 s annealing and elongation
step at 60◦C. Validated primer sets (GAPDH, Nurr1 and Pitx3)
were obtained from selected QuantiTect Primer Assays (Qiagen,
Austin, Texas). The fluorescence was measured after the exten-
sion step by the iQ5 Multicolor Real-time PCR detection sys-
tem (BioRad). After the thermocycling reaction, a melting curve
was performed with slow heating, starting at 55◦C and with a
rate of 0.5◦C per 10 s, up to 95◦C. The assay included a non-
template control (sample was substituted by RNase- Dnase-free
sterile water). All reactions ran in duplicates. The threshold cycle
(Ct) was measured in the exponential phase and therefore was
not affected by the possible limiting components in the reaction.
Data analysis was performed with BioRad iQ5 software (Bio-
Rad). Fluorescent reading from qPCR was quantitatively ana-
lyzed by determining the difference of Ct (1Ct) between Ct of
the target gene and GAPDH control housekeeping gene using the
comparative Ct method as described by Pfaﬄ’s formula (Pfaﬄ,
2001).
Protein Extraction and Western-Blot
For the western blotting analysis, after dissecting the SN and
striatum from all brain tissues, these regions were lysed on
ice in RIPA buffer (50mM Tris/HCl, pH 8.0, 150mM NaCl,
2mM sodium orthovanadate, 1% Nonidet-P40, 0.5% sodium
deoxycholate, 0.1% SDS, and 1% of a protease inhibitor mix-
ture containing AEBSF, pepstatinA, E-64, bestatin, leupeptin,
and aprotinin). The soluble fraction was obtained and equal
amounts of total cell lysates were loaded in each lane of a 10%
polyacrylamide gel. After electrophoresis and transfer onto a
polyvinylidene difluoride (PVDF) membrane, specific protein
bands were detected using appropriate primary antibodies (rab-
bit anti-Pitx3; rabbit anti-Nurr1; mouse anti-TH and mouse
anti-GAPDH and respective secondary antibodies conjugated to
horseradish peroxidase (anti-rabbit or anti-mouse) followed by
Enhanced Chemiluminescence (ECL) detection. Densitometric
analyses were performed by using the ImageQuant software
(Bio-Rad).
Statistical Analysis
Statistical analysis of group differences was performed using
GraphPad Prism 5.0 (GraphPad Software Inc., San Diego,
CA, USA) by one-way analysis of variance (ANOVA) fol-
lowed by Dunnett’s test for comparison with control condition
(Figures 2, 4, 5) or Two-Way ANOVA (Figure 3). Control and
MPTP values correspond to the contralateral sides of saline-
and MPTP-treated mice, respectively. All other conditions corre-
spond to ipsilateral sides of saline- orMPTP-treatedmice. Contra
and ipsilateral conditions are explained above in the Stereotaxic
FIGURE 2 | RA-NPs promote the survival of TH+ cells in the
MPTP-injured SN. Adult mice received RA-NPs, blank NPs or solubilized RA
by stereotaxic injections in the right striatum. MPTP or saline (0.9% sterile
NaCl) were administered intraperitoneally (i.p.) 3 days after stereotaxic
injections of NPs formulations. The SN region was collected 7 days after
MPTP or saline i.p. injections. (A) Quantitative analysis of TH+ cells in the SN
of control mice (saline, i.p.) injected with RA-NPs (RA-NPs + saline) or blank
NPs (blank NPs + saline). (B) Quantitative analysis of TH+ cells in the
contralateral SN of MPTP-treated mice and in the ipsilateral SN of RA-NPs-
and blank-treated MPTP mice. (C) Representative photomicrographs of SN
sections immunostained for TH of mice treated with RA-NPs followed by the
i.p. injection of saline or MPTP. Scale bar: 50µm. (D) TH protein levels in the
SN of saline, MPTP or RA-NPs+ MPTP treated mice. A representative
Western blot for 60 kDa TH and 37 kDa GAPDH expression is shown. Data are
expressed as the percentage of control and represent the mean ± SEM
(n = 3–8 mice). ∗∗∗P < 0.001, ∗∗P < 0.01 and ∗P < 0.05 compared to saline,
###P < 0.001 and #P < 0.05 compared to MPTP, using One-Way ANOVA
followed by Dunnett’s test.
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FIGURE 3 | RA-NPs increase TH+ fibers immunoreactivity in the
MPTP-injured striatum. Adult mice received RA-NPs or blank NPs by
stereotaxic injections in the right striatum. MPTP or saline were administered
i.p. 3 days after stereotaxic injections of NPs formulations. The striatum region
was collected 7 days after MPTP or saline i.p. injections. (A) Quantitative
analysis of the intensity and area occupied by TH+ fibers in control
(contralateral side; set to 100%) and in RA-NPs- or blank-treated saline mice
(ipsilateral sides). (B) Quantitative analysis of the intensity and area occupied
by TH+ fibers in contralateral striatum of MPTP-treated mice (set to 100%)
and in RA-NPs- and blank-treated MPTP mice (ipsilateral sides). Black bars:
Intensity; White bars: Area. Data are expressed as the percentage of control
(A) or MPTP (B) (both contralateral sides) and represent the mean ± SEM
(n = 2–4 mice). ∗∗∗P < 0.001 compared to saline and #P < 0.05 and
###P < 0.001 compared to MPTP, using Two-Way ANOVA. (C) TH protein
levels in the striatum of saline, MPTP or RA-NPs+ MPTP treated mice. A
representative Western blot for 60 kDa TH and 37 kDa GAPDH expression is
shown. Data are expressed as the percentage of saline and represent the
mean ± SEM (n = 3 mice). ∗P < 0.05 compared to saline and #P < 0.05
compared to MPTP, using One-Way ANOVA followed by Dunnett’s test.
Injection Section. Blank NPs were used as negative control. The
data are expressed as percentages of values obtained relative to
the control or MPTP and are represented as the means ± stan-
dard error of mean (SEM). Statistical significance was considered
relevant for p < 0.05.
Results
RA-NPs Induce Neuroprotection of the SN
Dopaminergic Neurons Against the
MPTP-Induced Lesion
In this work we evaluated the putative neuroprotective effect of
RA-NPs on a MPTP-induced mouse PD model. NPs were pre-
pared by the electrostatic interaction of polyethylenimine (PEI,
polycation) complexed with RA and dextran sulfate (DS, polyan-
ion) according to a methodology reported previously by us (Maia
et al., 2011). RA-NPs have a DS/PEI ratio of 0.2, yielding NPs that
are approximately 220 nm in diameter and have a positive net
charge (zeta potential of about 16mV). RA-NPs developed by us
ensure an efficient intracellular transport and controlled release
of RA. We have also demonstrated that pH enabled the control
of RA releasing from NPs showing that the RA exposed to pH 7.4
was rapidly released over 10 days followed by a steady increase
until day 21 (Maia et al., 2011). This pH is roughly the pH found
in the brain (Casey et al., 2010). In contrast to these days of expo-
sure to RA when delivered in NP formulations, the half-life of
free solubilized RA administered directly into the brain is only
for few hours. First, we did not find any statistical difference in
the percentage of TH+ cells in the SN of RA-NPs or blank NPs
ipsilateral sides compared with the contralateral sides (control) of
saline animals (Figure 2A). These results suggest that both RA-
and blank-NPs did not interfere per se with the DA neuronal
survival. The exposure to MPTP triggered approximately 50%
reduction of TH+ cells in SN as compared with the saline ani-
mals (p < 0.001) (Figures 2B,C). The intrastriatal injection with
RA-NPs significantly prevented the loss of DA neurons induced
by MPTP (p < 0.001) (Figures 2B,C). Additionally, the levels of
TH protein in the SN corroborate the above results, since the sig-
nificant decrease of TH protein levels induced byMPTP exposure
was reverted by the presence of RA-NPs (Figure 2D).
We also investigated the putative neuroprotective effect of
4 nM and 10µM solubilized RA. The concentration of 4 nM cor-
responds to the payload of RA present in 100 ng/ml RA-NPs,
whereas 10µM is the concentration of solubilized RA capable
of inducing a proneurogenic effect on SVZ cells in vitro (Maia
et al., 2011). The neuroprotective effect triggered by RA released
from NPs was more robust than the one observed with solubi-
lized 4 nM or 10µM RA (78.7 ± 3.9% of control, n = 2; 63.2
± 4.7% of control, p < 0.05, n = 3; respectively). As expected,
intrastriatal injections of blank NPs, used as a negative control,
were not able to protect TH+ neurons against the MPTP toxic-
ity, showing that RA is the source of neuroprotection for TH+
neurons. Altogether, these results suggest that the prophylactic
administration of RA-NPs was very effective in protecting SNDA
neurons against MPTP toxicity.
RA-NPs Support Dopaminergic Fiber Striatal
Innervations Against the MPTP-Induced Lesion
DA neuronal cell bodies present on the SN project axonal fibers
toward the striatum. Therefore, we performed TH immunohis-
tostainings in striatal coronal sections of adult mice in order
to analyze the putative trophic effects driven by RA released
from NPs on DA axonal fibers. The intensity and area occu-
pied by TH+ immunoreactive fibers were quantified in saline-
and MPTP-treated mice. No statistical difference was found in
the intensity (black bars) and area (white bars) occupied by
TH+ fibers in the contralateral striatum of saline-treated ani-
mals (line set to 100%) as compared to the ipsilateral side of
the same animals injected with RA- or blank-NPs (Figure 3A).
As expected, MPTP caused a significant decrease in the intensity
and percentage of area occupied by TH+ fibers as compared to
saline-treated animals (set to 100%) (Figure 3A). Pre-exposure
to RA-NPs significantly protected the TH+ fibers against MPTP
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induced degeneration (Figure 3B). As expected, the blank NPs
did not interfere with theMPTP toxicity (Figure 3B). In addition,
the same tendency regarding the TH protein levels was also found
in the striatum, reinforcing the neuroprotective effect of RA-NPs
against MPTP DA toxicity. The significant decrease of TH pro-
tein levels induced by MPTP was prevented by the injection of
RA-NPs (Figure 3C). These data suggest that RA-NPs might also
support DA neuronal projections present in the striatum.
RA-NPs Modulate Nurr1 and Pitx3 mRNA and
Protein Expression
To investigate possible molecular players involved in DA neu-
roprotection induced by RA-NPs, we then collected the SN and
the striatum from adult (2–3 months) or old (25–26 months)
mice. The aim of these experiments was tomimic the pathological
environment occurring in PD, since the most predominant form
of this disease (idiopathic) occurs in older individuals. We then
analyzed the expression of transcription factors involved in
DA development and survival—Nurr1 and Pitx3. Due to their
regional-specific expression pattern (Smidt et al., 1997; Saijo
et al., 2009), Nurr1 expression was evaluated in SN and striatum
whereas Pitx3 expression was evaluated only in the SN.
As shown in Figure 4A, the intrastriatal injection with
RA-NPs in saline-treated adult mice did not change the mRNA
expression levels of Pitx3 as compared to the contralateral hemi-
sphere (saline i.p.; line set to 100%). As expected, whenmice were
exposed to MPTP there was a significant decrease in the Pitx3
mRNA expression levels (p < 0.01). Accordingly, the decrease of
Pitx3 mRNA levels is compatible with the loss of nearly 50% of
TH+ neurons in SN induced by MPTP (Figure 2B). The admin-
istration of RA-NPs in the MPTP-treated adult mice significantly
prevented the decrease of Pitx3 mRNA levels in the SN as com-
pared to MPTP (p < 0.05) (Figure 4B). In accordance with pre-
vious data, blank NPs did not change Pitx3 mRNA expression as
compared withMPTP-only exposed cells (106.6± 11% ofMPTP;
n = 3). The protein levels of Pitx3 were in accordance with the
qPCR results, been significantly decreased in MPTP treated mice
and not altered in the presence of RA-NPs, both compared with
the saline group (Figure 4C).
qPCR analysis was also performed in old mice. First we
showed that the striatal administration of RA-NPs did not sig-
nificantly alter mRNA expression of Pitx3 as compared to saline-
treated animals (Figure 4A). As expected, a robust decrease
in Pitx3 mRNA levels was found in the hemisphere exposed
to MPTP as compared to saline-treated animals (p < 0.001;
Figure 4A). The administration of RA-NPs in MPTP-treated old
mice significantly prevented the decrease of Pitx3 mRNA levels
induced by MPTP (line set to 100%) (Figure 4B). Unfortunately
we could not evaluate the TH protein levels in the SN of old
mice due to the limited availability of mice with a substantially
advanced age.
Nurr1 mRNA expression levels were also analyzed in the SN
and striatum of both adult and old mice. The intrastriatal injec-
tion with RA-NPs in saline-treated adult mice did not change the
mRNA expression levels of Nurr1 in the striatum and SN (saline
mice; line set to 100%) (Figure 5A). When mice were exposed
to MPTP there was a significant decrease in Nurr1 transcripts
FIGURE 4 | RA-NPs induce the expression of transcription factor Pitx3
in the SN of adult and old mice exposed to MPTP. Adult and old mice
received RA-NPs by stereotaxic injections. Saline or MPTP were i.p.
administered 3 days after stereotaxic injections of nanoformulations in the right
striatum (ipsilateral side). Seven days after saline or MPTP injections, the SN
region was collected for measurement of Pitx3 mRNA expression by qPCR.
The expression levels were normalized to the GAPDH housekeeping gene.
(A,B) Bar graphs indicate the percentage of Pitx3 mRNA expression in adult
and old mice, expressed as the percentage of control (A) or MPTP (B). (C)
Pitx3 protein levels in the SN of saline, MPTP or RA-NPs+ MPTP treated adult
mice. A representative Western blot for 32 kDa Pitx3 and 37 kDa GAPDH
expression is shown. Data represent the mean ± SEM (n = 3–6 mice).
∗∗∗P < 0.001, ∗∗P < 0.01, and ∗P < 0.05 compared to saline and #P < 0.05
compared to MPTP, using One-Way ANOVA followed by Dunnett’s test.
levels in both striatum and SN (p < 0.01) (Figure 5A). The
administration of RA-NPs inMPTP-treated adult mice prevented
the decrease of Nurr1 mRNA levels induced by MPTP (line
set to 100%) (Figure 5C). In same conditions, no changes were
detected in Nurr1 mRNA levels in the striatum exposed to both
RA-NPs plus MPTP when compared with MPTP-only exposed
contralateral striatum (line set to 100%) (Figure 5C). In accor-
dance with previous data, blank NPs did not change Nurr1
mRNA expression in striatum and SN as compared with MPTP-
only exposed cells (72 ± 14.4% and 85.4 ± 11.9% of MPTP,
respectively; n = 3). Nurr1 protein levels in the SN of adult
mice were also evaluated. RA-NPs striatal injection prevented the
decrease of Nurr1 protein level as induced by MPTP exposure
(Figure 5D).
qPCR analysis regarding the expression of Nurr1 mRNA was
also performed in old mice. The striatal administration of RA-
NPs in saline-treated mice did not significantly alter both SN and
striatal mRNA expression of Nurr1 as compared to saline-treated
animals (control; line set to 100%) (Figure 5B). As expected, a
robust decrease in Nurr1 mRNA expression in the striatum and
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FIGURE 5 | RA-NPs induce the expression of transcription factor Nurr1
in MPTP-treated adult and old mice. Adult and old mice received RA-NPs
by stereotaxic injections. Saline or MPTP were i.p. administered 3 days after
stereotaxic injections with nanoparticle formulations in the right striatum
(ipsilateral side). Seven days after saline or MPTP injections, the SN and
striatum regions were collected for measurement of Nurr1 mRNA expression
by qPCR. The expression levels were normalized to the GAPDH housekeeping
gene. (A,B) Bar graphs indicate the percentage of Nurr1 mRNA expression in
adult and old mice, respectively, expressed as the percentage of control
(saline, contralateral). (C) Bar graph indicate the percentage of Nurr1 mRNA
expression in adult and old mice, relative to MPTP. Black bars: striatum; White
bars: SN. (D) Nurr1 protein levels in the SN of saline, MPTP or RA-NPs+MPTP
treated adult mice. A representative Western blot for 66 kDa Nurr1 and 37 kDa
GAPDH expression is shown. Data represent the mean ± SEM (n = 3–7 mice).
∗∗∗P < 0.001, ∗∗P < 0.01, and ∗P < 0.05 compared to saline and #P < 0.05
compared to MPTP using One-Way ANOVA followed by Dunnett’s test.
SN was found in the hemisphere exposed to MPTP as compared
to saline-treated animals (p < 0.001) (Figure 5B). The adminis-
tration of RA-NPs in MPTP-treated old mice significantly pre-
vented the decrease of Nurr1 mRNA levels in the striatum as
compared to MPTP (line set to 100%) (Figure 5C). In the same
conditions, the RA released from NPs prevented, at least in part,
the decrease of Nurr1 mRNA levels in the ipsilateral SN, but no
statistical difference was observed when compared to MPTP.
Discussion
In this study we have investigated the putative neuroprotective
role of RA in a mouse model of PD taking advantage of a recently
described nanoparticle delivery system developed by our group
(Maia et al., 2011; Santos et al., 2012). RA regulates multiple
biological processes including cell proliferation and differentia-
tion, by virtue of its ability to modulate the rate of transcription
of numerous target genes. It was also described that RA has a
protective role against neurodegeneration of mDA neurons in the
SN (Yin et al., 2012). However, in order to achieve protective or
trophic effects, RA requires a well regulated narrow concentra-
tion windowwhich posse difficulties in the delivery of therapeutic
doses. Recently we developed a nanoparticle formulation that
avoids the use of large concentrations of RA as well as controls
the use of toxic solvents such as DMSO and ensures intracel-
lular transport and controlled release of RA (Maia et al., 2011).
We showed that this RA-NPs formulation enhances subventricu-
lar zone neurogenesis both in vitro and in vivo, without affecting
cell survival and proliferation at the concentrations used in this
study (Santos et al., 2012). However, there are no studies using
this delivery system for DA neuroprotection in a context of PD.
PD is mainly characterized by a progressive and preferential loss
of DA neurons in SNpc which project their terminals to the stria-
tum (Jankovic, 2008). In this sense, in the first part of this study,
we investigated whether RA-NPs protect TH DA neurons from
MPTP-induced lesion by performing TH immunohistostainings
inmidbrain and striatal sections.We demonstrated that intrastri-
atal injections with RA-NPs before MPTP administration signifi-
cantly reduced the loss of TH+ cells and TH protein levels in the
ipsilateral SN to levels similar to control. Moreover this neuro-
protective effect induced by 100 ng/ml RA-NPs was more robust
than the effect of 10µM solubilized RA. In fact, the amount of
RA payload present in 100 ng/ml of RA-NPs corresponds to 4 nM
of RA and this concentration is 2500-fold lower than the con-
centration of 10µM solubilized RA (Maia et al., 2011). Similarly,
there was a significant reduction in intensity and area occupied
by TH+ fibers in contralateral striatum of MPTP-treated mice
and this reduction was counteracted by the presence of RA-NPs.
Our results are in line with previous findings by others showing
that RA can be an effective neuroprotective agent for DA neu-
rons. In fact, a recent report showed that the intranasal delivery
of 9cisRA, a less effective RA isomer, can also protect DA neu-
rons against neurodegeneration induced by 6-OHDA (Yin et al.,
2012). In the present study we used the atRA isomer, the main
biologically active form, since it is more stable than 9cisRA iso-
mer and can diffuse easily through the cellular membrane due
to its lipophilic nature. Moreover, robust results were observed
by performing a single intrastriatal administration of RA-NPs
before MPTP-induced injury. This approach seems to be par-
ticularly feasible because numerous studies have demonstrated
that intracerebral administration of several molecules (e.g., Neu-
ropeptide Y, INI-0602) is able to prevent DA loss in the lesioned
nigrostriatal DA system in PD animals models (Decressac et al.,
2012; Yin et al., 2012; Suzuki et al., 2014). In fact, RA-NPs were
injected in the striatum tomaximize the amount of RA that could
reach the dopaminergic terminals. Several authors using MPTP
intoxication protocols reported that there is a higher degree of
degeneration of DA terminals, concomitantly with the severe loss
of striatal DA content, than of the TH cell bodies found at the
SN. Therefore, dopaminergic degeneration is more severe at the
level of nerve endings than at the level of the nerve perikarya, a
concept compatible with the mechanism of MPTP action. Thus,
the stereotaxic injection of RA-NPs in the striatum could enroll a
neuroprotective effect directly in DA terminals in an early stage
of DA degeneration. Moreover, as soon as reliable biomarkers
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for PD will be discovered, this RA-NPs formulation can be also
used in an early stage of PD pathology to prevent or decelerate
the progression of this disease. It has long been recognized that
high concentrations or overexposure to RA causes widespread
toxic effects in humans (Penniston and Tanumihardjo, 2006).
Since the amount of RA per milligram of NPs is low, the use of
this formulation can help to overcome these toxic effects. Addi-
tional delivery routes, such as the intranasal delivery, should be
tested to clearly demonstrate the safety of our RA-NPs. However,
the bioavailability of RA-NPs in the nigrostriatal pathway of PD
patients that may present olfactory dysfunction, an early sign of
PD, should be taken in consideration. This NPs formulation was
also designed to facilitate the cellular internalization for delivery
of RA within cells (Maia et al., 2011). We cannot assert that the
beneficial effect provided by RA-NPs is due to a specific uptake by
DA neurons, but it can create a beneficial environment to them,
by modulating the expression of factors involved in survival of
these neurons, namely glial cell line-derived neurotrophic factor
(GDNF) and neurotrophin-3 (NT-3) or by suppressing inflam-
matory responses induced by activated glia (Thang et al., 2000;
Xu and Drew, 2006). Moreover, DA neurons express RAR recep-
tors, making these cells sensitive to the RA that can escape from
the NPs to interact with these intranuclear receptors. In fact, Kat-
suki and colleagues (Katsuki et al., 2009) showed that both RARα
and RARβ were highly expressed in DA neurons when compared
with weak expression found in microglia and astrocytes. Also,
treatment with Am80, a RARα/β agonist, triggered an increase
of immunoreactivity against RARα and RARβ in the DA neu-
rites, suggesting that RA released by nanoparticles that have been
incorporated into DA terminals/neurites can activate RARs in
DA neurons and trigger neuroprotection. This is in accordance
with several authors who showed that RA signaling is involved in
neurite outgrowth and axonal regeneration by regulating cAMP
levels, AKT phosphorilation and expression of the inhibitory
Nogo receptor (NgR) complex, among others (Puttagunta and Di
Giovanni, 2011).
Unfortunately, till date the precise pathogenesis of PD
remains largely unknown, however there are increasing evi-
dences suggesting that dysfunction of some transcription fac-
tors may be involved in the differentiation and survival of mDA
neurons which can be responsible for the development of PD
(Jankovic et al., 2005; Luk et al., 2013). Amongst them, Nurr1
and Pitx3 are the most extensively studied ones. Nurr1 is one of
the key regulators for the development and functional mainte-
nance of DA neurons and is also considered as a crucial regulator
for the expression of several genes involved in PD pathology
including dopamine transporter and TH (Smits et al., 2003). This
transcription factor was found predominantly expressed in DA
neurons but can also be expressed by microglia cells (Zetter-
strom et al., 1996; Saijo et al., 2009). Pitx3, another key factor for
the development of DA neurons, is exclusively expressed in the
DA cells present in the SN and ventral tegmental area of mid-
brain and is maintained throughout adult life in both rodents
and humans (Smidt et al., 1997). This study is the first to show
the modulation of Nurr1 and Pitx3 mRNA and protein expres-
sion using a RA-releasing NPs formulation. In a recent study,
it was shown that the mRNA expression of both Nurr1 and
Pitx3 were significantly decreased under PD conditions, suggest-
ing that both genes were potential susceptibility genes for PD
(Liu et al., 2012). Accordingly, in our experiments using both
adult and old mice, we observed that the MPTP induced a robust
decrease of both Nurr1 and Pitx3 mRNA levels, which is in line
with other results previously reported (Gibrat et al., 2009; Rojas
et al., 2012), and that the RA-NPs were able to counteract this
decrease. This effect mediated by MPTP is more robust in the
SN and striatum of older mice than in adult mice, which is in
agreement with the fact that older mice are more susceptible to
the toxic effects driven by MPTP as compared to adult mice.
This may occur because monoamine oxidase-B (MAO-B) activ-
ity increases with age leading to the accumulation of high levels of
MPP+ toxic form; thus both lethality and neurotoxicity of MPTP
are age-dependent (Jarvis andWagner, 1985). Because the risk of
developing PD by itself is associated with advancing age, the find-
ing that toxic actions of this neurotoxin also increase with age
has generated considerable interest. So, it is important to eval-
uate the effects of RA-NPs in older animals since age is a risk
factor of PD. For this reason, we also evaluated the effects of
RA-NPs in Nurr1 and Pitx3 mRNA expression in MPTP-treated
old mice. Surprisingly, the increased mRNA expression of Pitx3
was more robust in the SN of old mice treated with both RA-
NPs and MPTP than in adult mice. Since the differences found
between saline vs. MPTP-treated mice and MPTP- vs. MPTP +
RA-NPs-treated mice in terms of number of TH+ cells and Pitx3
mRNA levels were correlated in the adult mice, we can pre-
dict that the same relationship may occur in old mice. Regard-
ing Nurr1 expression, there was a drastic decrease in mRNA
expression in MPTP-lesioned striatum of old mice compared
with the Nurr1 mRNA expression in MPTP-lesioned striatum of
adult mice. This may occur since the cells of old mice are more
FIGURE 6 | Schematic summary of the effects mediated by RA-NPs
against MPTP-induced injury in the dopaminergic (DA) nigrostriatal
pathway of adult and old mice. The i.p. injection of MPTP induced a
decrease in TH DA neurons in SN and TH fibers in the striatum of adult mice
(A-red color). This effect was accompanied by a decrease in mRNA expression
of transcription factors involved in DA neuronal survival, Nurr1 and Pitx3, in SN
and striatum of both age groups (A,B-red color). In the adult mice, the RA
released from NPs protects the DA TH neurons in SN as well its neuronal TH
fibers/axonal innervations in the striatum against MPTP-induced injury
(A-green color). There was also an increase in Nurr1 and Pitx3 mRNA
expression levels only in SN of adult mice (A-green color). Under the same
conditions there was an increase in Pitx3 and Nurr1 mRNA expression in SN
and striatum of old mice, respectively (B-green color).
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sensitive to the MPTP toxic effects than adults, and with the fact
that MPTP also induces death of Nurr1-expressing microglia,
thus resulting in a drastic decrease in Nurr1 mRNA expression
in striatum (Serra et al., 2002). The pattern of Nurr1 mRNA
expression is different in SN and striatum of adult and old mice
treated with MPTP only and with RA-NPs. Our results suggest
that Nurr1 and Pitx3 may be RA target genes and, therefore,
RA can activate their transcription by binding to RAR-RXR het-
erodimers. The DA system is particularly susceptible to aging,
possibly as a result of age-related decrease in Nurr1 expression
that increases the vulnerability of the SN neurons to environmen-
tal stress (Chu et al., 2002). Nurr1 also has a role in inflamma-
tion by inhibiting the expression of pro-inflammatory neurotoxic
mediators by microglia and astrocytes. Reduced Nurr1 expres-
sion results in exaggerated inflammatory responses in microglia
that are further amplified by astrocytes leading to the produc-
tion of factors that cause death of DA neurons (Saijo et al., 2009).
Therefore, we can hypothesize that the decrease of Nurr1 with
age can create a pro-inflammatory milieu responsible for a DA
susceptibility to degeneration (Blasko et al., 2004). Several NPs
formulations have been reported to release drugs in the brain
as potential therapeutic strategies for PD (Garbayo et al., 2009;
Regnier-Delplace et al., 2013). Concerns related to solubility, sta-
bility or bioavailability of somemolecules make the use of bioma-
terials more frequent. However, the balance between biomaterials
and payload molecule must be well established since the bioac-
cumulation and concomitant toxicity can generate undesired
side-effects.
Conclusions
Herein, we reported for the first time the neuroprotective effect
on DA neurons triggered by RA released from NPs on a MPTP
mouse model for PD. In addition, these RA-NPs also induced
the expression of mRNA and protein of transcription factors
responsible for DA neuronal specification and survival, namely
Nurr1 and Pitx3 (Figure 6). Notably, this formulation offers a
significant advantage over solubilized RA. Thus, RA-NPs could
be an efficient/suitable strategy to prevent the onset of PD and
potentially to open new perspectives for the treatment of other
neurodegenerative diseases.
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